Search

Objective: To establish the prevalence of psychoactive drug consumption in an obese population., Material and Methods: We collected data from the clinical records of obese patients attending the Endocrinology and Nutrition Department and Psychiatry Department of Hospital del Mar between June 2005 and May 2006 (n=259). We recorded anthropometric, epidemiological and toxicological data. We also investigated the prevalence of concomitant diseases in this population., Results: Psychoactive drugs were consumed by 37% of obese patients, mainly antidepressants (27%), anxiolytics, sedatives and hypnotics, and anticonvulsants. Moreover, 15% of all patients received combination treatment with two or more psychoactive drugs, mostly the association of an antidepressant and an antiepileptic drug., Conclusion: The prevalence of psychoactive drug consumption in our sample was higher than prevalence data observed in the general population, with antidepressant consumption being three-fold higher., (Copyright 2009 SEEN. Published by Elsevier Espana. All rights reserved.)

Although metabolic syndrome is generally associated with type 2 diabetes mellitus, the present review emphasizes the possible presence of metabolic syndrome in type 1 diabetes and the impact of insulin resistance on micro- and macrovascular complications. Results of major intervention studies in type 1 diabetes have led to a generalized intensive insulin treatment, being an excessive weight gain one of the consequences. Since abdominal obesity and hyperglycemia are 2 components of the metabolic syndrome, an increase in the percentage of metabolic syndrome in patients with type 1 diabetes is not surprising, though its prevalence does not reach that reported for type 2 diabetes. For insulin sensitivity quantification in patients with type 1 diabetes the estimated glucose disposal rate (eGDR): it consists of calculating a score based on clinical factors of the patient, which shows an inverse relationship with the development of micro- and macrovascular complications. Moreover, insulin-resistance identification in type 1 diabetes may have therapeutic implications.